Engin Altintas

Intralesional steroid injection in benign esophageal strictures resistant to bougie dilation

Objective:  Some benign esophageal strictures are highly resistant to bougie dilation. The aim of this study was to determine whether intralesional steroid injection had additional benefit to Savary‐Gilliards bougie dilation therapy (SGBD).

Endoscopic Management of Biliary Obstruction Caused by Cavernous Transformation of the Portal Vein

BACKGROUND Symptomatic biliary obstruction caused by cavernous transformation of the portal vein is an extremely rare disorder for which there is no consensus as to optimal treatment. The results of endoscopic treatments in a small group of patients is reviewed. METHODS A total of 10 patients (5 men, 5 women; mean age 36.1 years, range 17-48 years) with severe biliary strictures were treated between 1995 and 2001. Biliary sphincterotomy was performed in all patients. Four patients also underwent balloon dilation, nasobiliary drainage, and stone or sludge extraction by using a balloon. All patients had stent insertion. OBSERVATIONS The mean duration of therapy was 3.3 years (range 1-7 years). There was no complication directly related to the endoscopic procedures except for hemobilia that occurred in one patient during stent removal. Cholangitis developed in 5 patients during the therapy period and was treated endoscopically. In 4 patients, significant improvement in the biliary stricture was observed and stents were removed in 3. These patients were followed without stent insertion for one year. CONCLUSIONS Endoscopic management of biliary stricture caused by cavernous transformation of the portal vein appears to be effective and safe.

Hepatobiliary fascioliasis: clinical and radiologic features and endoscopic management.

Fasciola hepatica is a zoonotic liver fluke that can cause disease in humans. Fascioliasis is an uncommon disease. We retrospectively analyzed 9 cases of fascioliasis and reviewed the relevant literature. A high index of suspicion and specific ultrasonographic findings are very helpful in the diagnosis of the disease. However, serological studies and endoscopic retrograde cholangiopancreatography confirm the diagnosis. The disease has 2 stages: hepatic stage and biliary stage. While several drugs are used during the hepatic stage, endoscopic retrograde cholangiopancreatography is particularly effective in the biliary stage.

Low efficacy rate of moxifloxacin-containing Helicobacter pylori eradication treatment: in an observational study in a Turkish population.

Background:  Standard triple therapy for Helicobacter pylori has an eradication rate of about 50% in Turkey. It may be due to an increased resistance of H. pylori to antibiotics. Therefore, we aimed to investigate the effectiveness of a new second‐generation fluoroquinolone, moxifloxacin‐containing triple therapy in H. pylori eradication.

Valsartan-Induced Hepatotoxicity in a HBs-Ag-Positive Patient

TO THE EDITOR: Hepatotoxicity caused by angiotensin II receptor blockers is a very rare disorder. We report the first case with acute hepatic injury associated with valsartan, which is an antihypertensive agent. A 52-yr-old hypertensive woman was admitted to our hospital with complaints of weakness, nausea, jaundice, and right subcostal abdominal pain. Her past medical history was unremarkable except for primary hypertension and hepatitis B surface antigen (HBs-Ag) positivity. She had been followed as a HBs-Ag carrier for 4 yr without clinical and laboratory symptoms and signs of acute or chronic liver disease in our hospital. She had been treated for primary hypertension by valsartan for 1 month. There was no other medication. The patient had manifested pruritic erytematous skin changes 1 wk before this admission. After this complaint, moderate nausea, jaundice, and right subcostal abdominal pain developed. On admission, her physical examination revealed no abnormality except for painful mild hepatomegaly. Laboratory findings were as follows: complete blood count was normal and eosinophilia was present. Her total and direct bilirubin levels were 3.2 mg/dl and 2.8 mg/dl, respectively, on admission, and peaked 7.8 and 6.9, respectively on the 7th day of admission. Liver enzymes peaked at the 6th day as follows: ALT 780 U/L, AST 1292 U/L, -glutamyl transferase 945 U/L, and liver-specific ALP 1840 U/L. Serological tests for hepatitis virus were negative (anti-hepatitis A virus IgM, anti-hepatitis B core IgM and IgG, hepatitis B virus DNA by polymerase chain reaction, hepatitis C virus antibody hepatitis C virus RNA by polymerase chain reaction, anti-Epstein-Barr virus IgM, and anti-cytomegalovirus IgM and IgG), except for HBs-Ag positivity. Markers for toxoplasmosis, herpes simplex virus, and HIV were all negative. International Normalized Ratio (INR) and PT were mildly elevated. Hepatobiliary ultrasonography revealed mild hepatomegaly. Liver biopsy was considered, but the patient refused. Valsartan therapy was discontinued at once. Hepatic failure and related complications were not seen. The complaints of the patient were resolved within 2 wk under conservative management. Liver enzymes and bilirubin levels decreased rapidly within 2 wk and returned to normal limits within 3 months. She has been followed for 6 months asymptomatically. As far as we know, this is the first case of valsartanassociated hepatotoxicity in a patient with HBs-Ag positivity. There is just one case report of valsartan-associated hepatic injury from Spain (1). There are not a lot of cases of angiotensin II receptor antagonists associated hepatotoxicity, and in this case, presumably this association is a hypersensitivity reaction together with pruritic skin changes. Valsartan is eliminated mainly by hepatic clearance. Headache, dizziness, and fatigue were the most common adverse events in placebocontrolled studies; the incidence of these adverse events was not significantly different between placebo and valsartan recipients (2). Rash and angioedema have been reported with angiotensin II receptor antagonists very rarely (3). Drug-induced hepatic injury associated with losartan was reviewed by Tabak et al. (4). The importance of HBs-Ag positivity in this hepatotoxicity remains unknown, and the physicians who recommended these agents should be careful about this complication.

Acute Upper Gastrointestinal Bleeding Due to Metastatic Lung Cancer: An Unusual Case

There have been several published reports on metastatic lesions in the stomach, but the number of cases have been limited due to the low frequency of the condition. Metastatic lesions in the stomach are usually asymptomatic. A 55-year-old man with known metastatic lung adenocancer exhibited epigastric pain, hematemesis, and melena. A bleeding, ulcerated gastric metastasis was found and treated with endoscopic therapy and omeprazole.

An unusual cause for massive upper gastrointestinal bleeding in children: Dieulafoy’s lesion

Dieulafoy’s lesion is a rare cause of severe upper gastrointestinal hemorrhage in children and predominantly occurs in the proximal stomach. We report a case of massive upper gastrointestinal bleeding in a 3-year-old boy that originated from a Dieulafoy’s lesion and was treated by epinephrine injection.

Mucosal mast cells in irritable bowel syndrome and inflammatory bowel disease.

Even though exciting progresses have been until now, further studies are necessary to clearly understand the significance of MMC. Mast cells are thought to participate in the pathogenesis of inflammatory bowel disease and irritable bowel syndrome. However, their role in the pathogenesis remains unsettled. The specific aims of this study were to (1) examine mucosal mast cell counts in the cecum in patient with IBS, and IBD (2) compare MMC between the disease groups. We showed increased MMC count in IBS.

Ectopic opening of the common bile duct into various sites of the upper digestive tract: a case series

BACKGROUND Ectopic opening of the common bile duct (CBD) into the GI tract is an extremely rare congenital anomaly. The clinical implications and frequency of this anomaly are not clearly known. OBJECTIVE To present a case series of ectopic opening of the CBD into various sites of the upper digestive tract and discuss clinicopathological features of this condition. DESIGN AND SETTING Retrospective, observational study in a single tertiary care medical center. PATIENTS Consecutive patients undergoing ERCP who received a diagnosis of an ectopic opening of the CBD between September 2001 and August 2009 were reviewed. INTERVENTIONS Endoscopic and cholangiographic findings were reviewed. MAIN OUTCOME MEASUREMENTS The endoscopic and cholangiographic findings and clinical course of these patients were reviewed. RESULTS During the study period, 1040 patients underwent ERCP. A total of 11 patients (6 men and 5 women with a median age of 59.2 years) received a diagnosis of an ectopic opening of the CBD. The opening sites of the CBD were located as follow: 1 in the stomach, 4 in the duodenal bulb, 3 at a more lateral site of the second portion of the duodenum, and 3 in the third part of the duodenum. Seven patients had choledocholithiasis, 2 had acute pancreatitis, and 3 had severe cholangitis. CONCLUSION Although an ectopic opening of the CBD is rare, it may be associated with severe pancreaticobiliary disorders. Endoscopists should be aware of this anomaly and know what to do in case they encounter the condition.

An unusual cause of duodenal obstruction: mesenteric fibromatosis in a patient with type I Mayer-Rokitansky-Kuster-Hauser syndrome.

Patients with mesenteric fibromatosis (MF) are clinically asymptomatic, with little or no focal symptoms until later in their course, at which time they complain of pain, abdominal discomfort, constipation, vomiting, abdominal mass, weight loss, and symptoms due to organ compression. Generally, it occurs as an abdominal mass but may also present in many different ways. In some cases, trauma, previous abdominal surgery, and hormonal stimulation (such as estrogen) may play a role in onset of this neoplasm. Patients with Mayer-Rokitansky-Kuster-Hauser syndrome present primary amenorrhea and may have some other anomalies, including hearing defects, heart defects, skeletal deformities, and genital neoplastic diseases. We diagnosed duodenal obstruction due to MF in a patient with type I Mayer-Rokitansky-Kuster-Hauser syndrome.